ArticleAnnals of surgical oncology2025
Oncological Resectability Criteria for Intrahepatic Cholangiocarcinoma: A Preoperative Framework for Multidisciplinary Management.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Imaging of mass-forming intrahepatic cholangiocarcinoma: from detection to personalized treatments.Abdominal radiology (New York) · 2026Review
- ASO Editorial Comment: Beyond the Margin: Why Biology, More Than Technique, Defines Surgical Resectability for Locally Advanced Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Review
- Tumor Burden Modifies the Prognostic Impact of Adequate Lymph Node Dissection in Patients Undergoing Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Tumor Burden and the Prognostic Relevance of Adequate Lymph Node Dissection in Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection.Journal of gastrointestinal oncology · 2026Article
- Anatomic-Biologic Borderline Resectability Criteria Improve Recurrence Risk Stratification in Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Immunotherapy-Based Conversion to Curative-Intent Treatment in Hepatocellular Carcinoma: A Multidisciplinary Framework.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecent advancements in systemic chemotherapy have fueled debates regarding the feasibility of combining systemic therapy with surgery for advanced intrahepatic cholangiocarcinoma (ICC). However, the absence of consensus on oncological resectability criteria has hindered discussions on optimal multidisciplinary management. This study sought to propose preoperative oncological resectability criteria for ICC.
methodsPatients undergoing upfront curative-intent hepatectomy for ICC were identified from an international multi-institutional database. Independent tumor-related prognostic factors for overall survival were identified by using multivariable Cox regression and utilized to develop resectability criteria.
resultsAmong 953 patients, four independent tumor-related predictors of poor prognosis were identified: lymph node metastasis (LNM) on imaging (HR 1.3, 95% confidence interval [CI] 1.07-1.59), tumor size > 5 cm (hazard ratio [HR] 1.52, 95% CI 1.25-1.85), multinodular lesions (HR 2.03, 95% CI 1.64-2.52), and major vascular invasion (HR 1.64, 95% CI 1.34-2.01). High-risk points were identified based on a point system associated with the hazards of each factor: 1 point each for LNM, tumor size > 5 cm, and major vascular invasion, and 2 points for multinodular lesions. Patients were categorized as resectable (R) for scores of 0-1 or borderline resectable (BR) for scores ≥ 2. Patients with BR disease (n = 385, 40.4%) had markedly worse median overall survival versus individuals with R disease (n = 568, 59.6%) (24.6 months vs. 69.7 months, p < 0.001). Validation in an external cohort confirmed these findings.
conclusionsThe proposed preoperatively assessable resectability criteria can help differentiate BR versus R disease among ICC patients. These criteria offer a practical framework for preoperative risk stratification, aiding in treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.